Navigation Links
Sagent Pharmaceuticals Announces Launch of Fluconazole Injection in Premix Ready-to-Use IV Bags
Date:8/27/2009

SCHAUMBURG, Ill., Aug. 27 /PRNewswire/ -- Sagent Pharmaceuticals, Inc., a privately held specialty pharmaceutical company, today announced that it has launched fluconazole injection in premix bags. IMS Health estimates that 2008 U.S. sales of fluconazole injection approximated $18 million. Sagent will begin marketing and shipping fluconazole bags immediately.

"Our commitment to hospital safety is again exemplified in our new fluconazole offering, the most recent addition to our growing line of premixed IV bags," said Ravi Malhotra, vice president of project management for Sagent Pharmaceuticals. "The labeling and packaging of our fluconazole premix bag offerings are intended to clearly distinguish and differentiate each of the two dose sizes from the other and from similar products, thereby helping to reduce the potential for medication errors commonly caused by inadvertent use of the wrong product or dosage."

Sagent's fluconazole is available in 200 mg per 100 mL and 400 mg per 200 mL premix bags and is latex and preservative free.

About Fluconazole

Fluconazole injection is the generic equivalent of Pfizer's Diflucan(R). It is indicated for the treatment of oropharyngeal and esophageal candidiasis, cryptococcal meningitis, and for prophylactic administration to decrease the incidence of candidiasis in patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy. Fluconazole injection is approved for intravenous infusion only.

The most common adverse effects for patients receiving fluconazole include upset stomach, loss of appetite, altered sense of taste, diarrhea, headache, dizziness and fatigue.

About Sagent Pharmaceuticals, Inc.

Sagent Pharmaceuticals, founded in 2006, is a privately held specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products. Sagent has created a unique, global network of resources, comprised of rapid development capabilities, sophisticated manufacturing and innovative drug-delivery technologies, quickly yielding an extensive portfolio of pharmaceutical products that fulfills the evolving needs of patients. Sagent currently has more than 200 products in development.

To Discover Injectables Excellence(TM) and learn more about Sagent, please visit www.SagentPharma.com.


'/>"/>
SOURCE Sagent Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Sagent Pharmaceuticals Announces Launch of First Two Oncolytic Products: Fludarabine Phosphate for Injection, USP and Epirubicin Hydrochloride Injection
2. Sagent Pharmaceuticals Enters Into a $15 Million Revolving Credit Facility
3. Sagent Pharmaceuticals Announces Extension of Series A Financing
4. Sagent Pharmaceuticals Announces U.S. FDA Approval of Azithromycin for Injection
5. Sagent Pharmaceuticals Announces Presentations at Upcoming Lazard Capital Markets and Piper Jaffray Healthcare Conferences
6. Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP
7. Sagent Pharmaceuticals Launches Ciprofloxacin Injection, USP, 5% Dextrose Premix Bag
8. Sagent Pharmaceuticals Inc. Completes $53 Million Series A Financing
9. Hisamitsu Pharmaceutical Announces Expiration of Subsequent Offering Period and Completion of Tender Offer for Outstanding Shares of Noven Pharmaceuticals
10. DURECT Signs Long Term Excipient Supply Agreement With King Pharmaceuticals for REMOXY(R)
11. Cumberland Pharmaceuticals Reports Second Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... ... care communications company offering education, research and medical media, has launched ... working in infectious diseases. , As the all-inclusive resource for infectious disease ...
(Date:2/10/2016)... ... February 10, 2016 , ... MetLoop CEO Jay Southerland ... version at the International Roofing Expo in Orlando, Florida on February 17-19. , ... advanced weather technology in the hands of consumers, roofing contractors, manufacturers and distributors,” ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... and Video Remote Interpreting (VRI) within Healthcare, recently partnered with Heart City ... interpreting (VRI). , For nearly 23 years, Heart City Health Center has provided ...
(Date:2/10/2016)... Huntington, NY (PRWEB) , ... February 10, 2016 ... ... web-based compliance tracking solution, The Guard, to associations of medical professionals throughout the ... HIPAA compliance, including security risk assessments, policies and procedures, employee training, regulatory updates, ...
(Date:2/10/2016)... ... ... Emergency rooms provide emergency care to stabilize critical health issues, but emergency dental ... at risk of losing a tooth or their smiles. Dr. Marine Martirosyan, dentist ... include:, , Avulsed or knocked-out teeth , Dislodged ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... -- Resolve Therapeutics, LLC, a clinical stage biopharmaceutical company ... of lupus and Sjogrens syndrome, today announced the ... in patients with systemic lupus erythematosus (SLE) with ... --> Data from a multicenter ... RSLV-132 in 32 subjects with SLE demonstrate the ...
(Date:2/10/2016)... NEW YORK , Feb. 10, 2016 ... clinical-stage biopharmaceutical company, announced today that it has filed ... Myeloid Leukemia and other cancers. --> ... of treating cancer by administration of Ceplene (histamine dihydrochloride) ... also provides methods of predicting the efficacy of Ceplene ...
(Date:2/10/2016)... A Worldwide Clinical Trials expert will ... Victoria Park Plaza in London , 24-25 ... and future advances for late phase research on Wednesday, 24 ... , associate director of project management at Worldwide, will focus ... regulations and standards in late phase research. ...
Breaking Medicine Technology: